Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference
February 09, 2023 16:01 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Provides 2023 Outlook
January 06, 2023 07:01 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China
November 29, 2022 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates...
Aclaris Therapeutics Announces Key Leadership Transitions
November 22, 2022 16:01 ET
|
Aclaris Therapeutics, Inc.
- Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr....
Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences
November 10, 2022 16:01 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 08, 2022 07:00 ET
|
Aclaris Therapeutics, Inc.
- Completed Enrollment in Phase 2a Trial of Zunsemetinib in Hidradenitis Suppurativa; Topline Data Expected in Mid-first Half of 2023 - Announced Patent License Agreement with Lilly for the Treatment...
Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations
September 27, 2022 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 30, 2022 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata
August 25, 2022 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
August 03, 2022 07:00 ET
|
Aclaris Therapeutics, Inc.
•Appointed Douglas Manion, M.D., FRCP (C), as President and COO •Initiated Phase 2a Study Activities for Psoriatic Arthritis WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics,...